Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study.
Fiche publication
Date publication
août 2021
Journal
ESMO open
Auteurs
Membres identifiés du Cancéropôle Est :
Dr EYMARD Jean-Christophe
Tous les auteurs :
de Wit R, Wülfing C, Castellano D, Kramer G, Eymard JC, Sternberg CN, Fizazi K, Tombal B, Bamias A, Carles J, Iacovelli R, Melichar B, Sverrisdóttir Á, Theodore C, Feyerabend S, Helissey C, Foster MC, Ozatilgan A, Geffriaud-Ricouard C, de Bono J
Lien Pubmed
Résumé
There is growing evidence that a high neutrophil-to-lymphocyte ratio (NLR) is associated with poor overall survival (OS) for patients with metastatic castration-resistant prostate cancer (mCRPC). In the CARD study (NCT02485691), cabazitaxel significantly improved radiographic progression-free survival (rPFS) and OS versus abiraterone or enzalutamide in patients with mCRPC previously treated with docetaxel and the alternative androgen-receptor-targeted agent (ARTA). Here, we investigated NLR as a biomarker.
Mots clés
abiraterone, cabazitaxel, enzalutamide, metastatic castration-resistant prostate cancer, neutrophil-to-lymphocyte ratio, prognostic factor
Référence
ESMO Open. 2021 Aug 24;6(5):100241